Search Results

You are looking at 1 - 1 of 1 items for

  • Author: Pierre Zelissen x
Clear All Modify Search
Marcus Quinkler Endocrinology in Charlottenburg, Berlin, Germany

Search for other papers by Marcus Quinkler in
Google Scholar
PubMed
Close
,
Bertil Ekman Departments of Endocrinology and Medical and Health Sciences, Linköping University, Linköping, Sweden

Search for other papers by Bertil Ekman in
Google Scholar
PubMed
Close
,
Claudio Marelli Shire International GmbH, Zug, Switzerland

Search for other papers by Claudio Marelli in
Google Scholar
PubMed
Close
,
Sharif Uddin Shire, Lexington, Massachusetts, USA

Search for other papers by Sharif Uddin in
Google Scholar
PubMed
Close
,
Pierre Zelissen Department of Internal Medicine and Endocrinology, University Medical Center Utrecht, Utrecht, the Netherlands

Search for other papers by Pierre Zelissen in
Google Scholar
PubMed
Close
,
Robert D Murray Department of Endocrinology, Leeds Teaching Hospitals NHS Trust, St James’s University Hospital, Leeds, UK

Search for other papers by Robert D Murray in
Google Scholar
PubMed
Close
, and
on behalf of the EU-AIR Investigators
Search for other papers by on behalf of the EU-AIR Investigators in
Google Scholar
PubMed
Close

Objective

Prednisolone is used as glucocorticoid replacement therapy for adrenal insufficiency (AI). Recent data indicate that its use in AI is associated with low bone mineral density. Data on risk factors for cardiovascular disease in patients with AI treated with prednisolone are scarce, despite this condition being the predominant cause of excess mortality. We aimed to address this question using real-world data from the European Adrenal Insufficiency Registry (EU-AIR).

Design/methods

EU-AIR, comprising of 19 centres across Germany, the Netherlands, Sweden and the UK, commenced enrolling patients with AI in August 2012. Patients receiving prednisolone (3–6 mg/day, n = 50) or hydrocortisone (15–30 mg/day, n = 909) were identified and grouped at a ratio of 1:3 (prednisolone:hydrocortisone) by matching for gender, age, duration and type of disease. Data from baseline and follow-up visits were analysed. Data from patients with congenital adrenal hyperplasia were excluded.

Results

Significantly higher mean ± s.d. total (6.3 ± 1.6 vs 5.4 ± 1.1 mmol/L; P = 0.003) and low-density lipoprotein (LDL) cholesterol levels (3.9 ± 1.4 vs 3.2 ± 1.0 mmol/L; P = 0.013) were identified in 47 patients on prednisolone vs 141 receiving hydrocortisone at baseline and at follow-up (P = 0.005 and P = 0.006, respectively). HbA1c, high-density lipoprotein and triglyceride levels, body mass index, systolic and diastolic blood pressure and waist circumference were not significantly different.

Conclusions

This is the first matched analysis of its kind. Significantly higher LDL levels in patients receiving prednisolone relative to hydrocortisone could predict a higher relative risk of cardiovascular disease in the former group.

Open access